Foghorn Therapeutics INC 8-K filings

Foghorn Therapeutics announced its second quarter 2026 financial and corporate update, detailing progress in its oncology and immunology programs, a strong cash position, and advancing clinical trials.

Foghorn Therapeutics stockholders re-elected directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Foghorn Therapeutics announced its first-quarter 2026 financial results and provided an update on its clinical and preclinical programs, highlighting progress in its FHD-909 collaboration with Lilly and advancements in its degrader programs.

Foghorn Therapeutics announced new preclinical data for its FHD-909 inhibitor and degrader programs targeting CBP, EP300, and ARID1B at the 2026 AACR Annual Meeting.

Foghorn Therapeutics Inc. announced the appointment of Ryan D. Maynard, a seasoned biopharmaceutical executive, as its new Chief Financial Officer, effective immediately.

Foghorn Therapeutics announced a $50 million equity financing at a 30% premium and provided positive updates on its oncology pipeline programs.

Foghorn Therapeutics Inc. announced the appointment of Jeff Sacher as interim Chief Financial Officer and Treasurer, effective immediately.

Foghorn Therapeutics highlights its leadership in chromatin biology, advancing a broad oncology pipeline including a Phase 1 SMARCA2 inhibitor partnered with Lilly and multiple degrader programs.

Foghorn Therapeutics announced its third-quarter 2025 financial results, reporting a narrowed net loss and pipeline progress, alongside the resignation of its Chief Financial Officer.

Foghorn Therapeutics announced significant preclinical progress across its Selective ARID1B, CBP, and EP300 degrader programs, highlighting potential new oncology therapies.

Foghorn Therapeutics provides an investor update detailing significant progress in its oncology pipeline, including its Phase 1 FHD-909 program with Lilly, and robust preclinical data for multiple degraders.

Foghorn Therapeutics reported reduced net losses and strong cash reserves, alongside significant progress in its oncology pipeline, including its lead candidate FHD-909 and multiple selective degrader programs.

Foghorn Therapeutics Inc. has entered into a new long-term lease for a larger facility in Watertown, MA, while simultaneously terminating its existing lease in Cambridge, MA, signaling a strategic relocation and expansion of its operations.

Foghorn Therapeutics Inc. announced that all proposals, including the election of four Class II directors and the ratification of Deloitte & Touche LLP as its independent auditor, were approved by stockholders at its 2025 Annual Meeting.

Foghorn Therapeutics reported its Q1 2025 financial results, highlighting progress in its clinical and preclinical programs and a cash runway into 2027.

Foghorn Therapeutics appoints Neil Gallagher and Stuart Duty to its Board of Directors, effective May 1, 2025, to leverage their expertise in biotechnology and finance.

Foghorn Therapeutics highlights preclinical data for FHD-909, selective CBP degrader, and selective EP300 degrader programs, along with a pipeline update, at the AACR 2025 Annual Meeting.

Foghorn Therapeutics showcases its first-in-class precision therapies and strategic partnership with Lilly in a March 2025 investor presentation.

Foghorn Therapeutics amended its common stock sales agreement with TD Securities, reducing the potential offering size from $200 million to $100 million.

Foghorn Therapeutics reports a strong cash position and progress in its clinical programs, including the Phase 1 trial of FHD-909 for SMARCA4 mutated cancers.

Foghorn Therapeutics is progressing its pipeline of first-in-class precision therapeutics, with multiple programs advancing towards clinical trials and key data readouts expected through 2026.

Foghorn Therapeutics received a notice from Nasdaq for non-compliance with audit committee requirements following a director's resignation, triggering a cure period to regain compliance.

Foghorn Therapeutics announces strategic objectives for 2025, highlighting progress in inhibitor and degrader programs, including FHD-909 and selective degradation of ARID1B.

Adam M. Koppel, M.D., Ph.D., has resigned from the Foghorn Therapeutics Board of Directors, effective immediately, with no reported disagreements.

Foghorn Therapeutics will discontinue independent development of FHD-286 in AML, prioritizing its proprietary pipeline and collaboration with Lilly.

Foghorn Therapeutics reported its third quarter 2024 financial results, highlighted by the first patient dosed with FHD-909 and advancements in multiple clinical and preclinical programs.

Foghorn Therapeutics has initiated a Phase 1 clinical trial for FHD-909, a selective SMARCA2 inhibitor, in patients with SMARCA4 mutated solid tumors, primarily targeting non-small cell lung cancer.

Foghorn Therapeutics reported its second quarter 2024 financial results, highlighted by a successful $110 million financing and progress in its clinical and preclinical programs.

Foghorn Therapeutics successfully held its 2024 Annual Meeting, electing three Class I directors and ratifying Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2024.

Foghorn Therapeutics is progressing its pipeline of first-in-class precision therapeutics, with multiple programs advancing into clinical trials and preclinical development.